Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients

Summary

This study provided a comparison of secukinumab to placebo with respect to skin inflammation as measured by skin exams in comparison to skin biopsies, adipose tissue and blood sample analyses.

Timeline

Start

2017-04-18

Primary completion

2018-04-25

Completion

2019-02-26

Outcome

Met primary endpoint

registry analysis (other test); Secukinumab 300 mg vs Placebo; difference in percentages 76.1 (95% CI 63.3 to 88.8); 95% confidence interval NCT03055494 ↗

registry analysis (other test); Secukinumab 300 mg vs Placebo; difference in percentages 55.8 (95% CI 42.3 to 69.3); 95% confidence interval NCT03055494 ↗

Publications

• Shishido-Takahashi N, Garcet S, Cueto I, Hur HB, Muscianisi E, Steadman J, Blauvelt A, Krueger JG. Cutaneous adipose tissue carries a strong inflammatory signature in patients with psoriasis. JCI Insight. 2026 Mar 3;11(7):e194171. doi: 10.1172/jci.insight.194171. eCollection 2026 Apr 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Secukinumab	Monoclonal antibody	300 mg	Subcutaneous

Indications